Figure 3
YOVAL1.1 tumors are responsive to immune checkpoint blockade in vivo. (a,b) Response of YUMM1.1 (a) and YOVAL1.1 (b) tumors to immunotherapy. Tumor growth and survival in response to combination anti-PD-1 and anti-CTLA-4 or isotype controls in C57BL/6 mice, n = 10–12. (c,d) YOVAL1.1 tumor growth in response to anti-PD-1 (c) or anti-CTLA-4 (d) or isotype controls. (a–d) Survival measured as time for tumors to reach >1200 mm3, arrows indicate treatment days. ns – not significant, Log-rank (Mantel-Cox) test, error bars show ±SEM. ****p < 0.0001.
